Copy
Having trouble viewing this message? View this email in a browser.
Share Share
Share Share
Forward Forward

AAFA’s Advocacy in Action 

From arranging a congressional briefing to pushing to improve access to epinephrine, AAFA advocates are a constant presence on Capitol Hill. 

Allergen Labeling on Alcohol 

On Nov. 8, AAFA co-hosted a briefing to Congress on the importance of allergen labeling for alcohol. The briefing titled, “The Case for Mandatory Alcohol Labeling,” raised awareness that common allergens such as milk and egg can be in alcohol. AAFA co-hosted the event with the Center for Science in the Public Interest (CSPI), the Consumer Federation of America (CFA), Food Allergy Research & Education (FARE), and the National Consumers League (NCL). AAFA shared the patient perspective on why mandatory allergen labeling of alcohol is critical to our community.  

Expanding Access to Life-Saving Epinephrine 

Nearly one in 50 people in the U.S. are at risk for anaphylaxis. Anaphylaxis can be triggered by allergies to food, insects, medicines, and latex. The first-line treatment for anaphylaxis is epinephrine. It comes in easy-to-use devices, such as auto-injectors. It can occur suddenly and get worse fast. It’s important to give epinephrine right away.  

If passed, Dillon’s Law would legally allow trained people to carry and give epinephrine in an emergency. Dillon's Law is named after Dillon Mueller, a teenage boy whose life was cut short due to a severe allergic reaction to a bee sting. Dillon had never had such a reaction before and did not have a prescription for epinephrine. This bill honors his memory and aims to prevent similar tragedies.  

You can support this critical legislation today by asking Congress to support Dillon’s Law. Send a message to your congressperson now. 

Join AAFA in Making an Impact

AAFA  raises awareness of issues such as the importance of access to epinephrine and the potential dangers of allergens in alcohol.  

Your support makes it possible to hold congressional briefings and to move life-saving legislation forward. 

Will you give today to ensure people with asthma and allergies have a strong voice on Capitol Hill? 

 

DONATE TODAY


Thanks to your ongoing generosity and engagement, we’ve made a difference in the lives of people who live with or manage asthma and allergies. Read about how we’re working together to improve health and empower people to have a voice inI decisions that affect their lives

RESEARCH NEWS

Here's the latest asthma and allergy research news:

Allergy 

Asthma 

Atopic Dermatitis 

Food Allergy 

CLINICAL TRIALS

NATRON Study for Hypereosinophilic Syndrome (HES) Is Seeking Eligible Participants   

Do you or your child have hypereosinophilic syndrome (HES)? The NATRON study is now enrolling patients 12 and older.  

Those who qualify may receive:  

  • Study-related care from local doctors at no cost  

  • Study medication at no cost  

  • Reimbursement for reasonable trial-related travel expenses  

There is no obligation, so answer a few questions now to see if you or your child may qualify to participate.  

Click below to learn more about the study, including a message from Dr. Princess Ogbogu, MD, and find out if you/your child may qualify to take part in the NATRON study.  


Are You Currently Taking Oral Corticosteroids (OCS) for Your Asthma? 

Would you like to contribute to important new research? SUNRISE is a clinical study investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for OCS in adults with severe asthma. The study is looking for people who: 

  • Are between 18 and 80 years of age 

  • Have had an asthma diagnosis for at least 1 year 

  • Have been taking OCS for asthma for at least 6 months 

  • Have been using inhaled corticosteroids for at least a year, and a long-acting beta 2-agonist (LABA) for at least 3 months 

  • Have not been receiving any biologic treatment for asthma for at least 4 months 

Sponsored by AstraZeneca 

                                                          LEARN MORE 

Now Accepting Patients for National Asthma Study


Are you a young adult between the ages of 18 and 30, African American or Black, with persistent asthma? Are you looking to get better control of your asthma? A national study is now accepting patients to test various mobile health programs. If you qualify for the study, you will be asked to use a mobile health program for about 10 weeks and complete four 30-minute questionnaires spread out over the course of one year. Everything is remote – you won’t have to come in for any study visits.

You will receive compensation for completing the study and will be given a Garmin physical activity tracker which you can keep after the study has ended.

Learn more about the study and see if you qualify.  

If you have any questions, please contact us at: 734-489-1949 or theathenaproject2022@gmail.com

INTERVIEWS AND FOCUS GROUPS

Research Opportunity: Caregivers for Children with Asthma


A Doctor of Nursing Practice (DNP) student at Regis College is recruiting for a project about caregivers and how well they cope with mental health symptoms while caring for a child with asthma. Your participation may help other caregivers like you. To be eligible, you must:

  • Have a child of any age with a diagnosis of asthma who requires albuterol or steroid inhalers for management
  • Be 18 years of age or older

You will be asked to complete a one-time, 15-minute survey about yourself and participate in a one-hour interview over Zoom in a group setting. You will be given a small reward at the completion of this project.

If you have any questions, please contact Timarra Warren by email or phone at: twar860@regiscollege.edu or 470-541-8440.
 

LEARN MORE

Share Your Thoughts on the Effects of Sesame Labeling  

If you or someone you provide care for has a sesame allergy, we would like to ask you about recent sesame allergen labeling legislation. A project at the University of South Carolina is compiling stories to describe the impact of the FASTER Act on people managing sesame allergies.  

  

Contact Richie Holmberg at the University of South Carolina for more information and to participate in this study: holmberr@email.sc.edu  
 

                                                                LEARN MORE

 

Now Recruiting Participants for Chronic Hives Interviews 

AAFA is looking for people who manage chronic hives – known as chronic spontaneous urticaria (CSU) – to interview for a research project. The interview will provide an opportunity for you to share your firsthand experiences and needs when managing CSU. Collected feedback will help AAFA develop and improve our CSU resources. 

The discussion should take about 30-45 minutes and can be scheduled at your convenience. If you are chosen to participate in an interview, we will provide a reward for your time. If you would like to participate in an interview, please take this quick survey to see if you are eligible. 

                                                             LEARN MORE 

CME OPPORTUNITIES

Moderate-to-Severe Asthma 

Ending Nov. 29! During “Applying the Latest Guidelines and Recommendations to Initiate Biologic Therapy and Control Moderate-to-Severe Asthma Symptoms,” an expert panel discussed the burden of uncontrolled moderate-to-severe asthma and current data on the efficacy and safety of biologics for treating asthma. Watch on demand.  

CSU and CIndU 

Don’t miss this CME program on treating chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU): “The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeted Agents.” An expert panel discussed strategies to identify urticaria subtypes, how to optimize the treatment of CSU and CIndU and much more. Watch on demand.

Did You Miss Our Last Issue?


Check out our earlier issue to learn about cold weather and asthma, insurance updates, and lung function.

 

READ THE LATEST ISSUE

Thank you for your continued support.
Visit aafa.org, aafa.org/certifiedkidswithfoodallergies.org

FOLLOW US:
Facebook Facebook
Instagram Instagram
YouTube YouTube
LinkedIn LinkedIn
Disclaimer: This newsletter is provided to you as a member and subscriber benefit and your use of it is in accordance with our website's terms of service.

Asthma and Allergy Foundation of America makes no representation, whatsoever, for the contents that may be contained in any of the sponsors or advertisers in this newsletter or the quality of any products, information, or other materials displayed, purchased or obtained by you as a result of an offer in connection with any advertisement. 

Please follow the instructions at the bottom of the newsletter to unsubscribe if you no longer wish to be on our newsletter mailing list. This newsletter is sent to all newsletter subscribers, registered members and donors of Asthma and Allergy Foundation of America.

Copyright © 2023 Asthma and Allergy Foundation of America, All rights reserved. ISSN 1939-8166.